Blood serum 48 kDa form of unconventional myosin 1c characterizes the early stage of multiple sclerosis

Authors

  • N. O. Nehrych Danylo Halytsky Lviv National Medical University, Ukraine,
  • T. I. Nehrych Danylo Halytsky Lviv National Medical University, Ukraine,
  • S. L. Myronovskyi Institute of Cell Biology, NAS of Ukraine, Lviv,
  • M. S. Shorobura Danylo Halytsky Lviv National Medical University, Ukraine,
  • O. I. Nehrych Danylo Halytsky Lviv National Medical University, Ukraine,
  • Yu. Ya. Kit Institute of Cell Biology, NAS of Ukraine, Lviv,
  • R. S. Stoika Institute of Cell Biology, NAS of Ukraine, Lviv,

DOI:

https://doi.org/10.14739/2310-1210.2018.4.135589

Keywords:

multiple sclerosis, biomarkers, unconventional myosin 1c, clinical course, early stage

Abstract

In accordance with the modern ideas of multiple sclerosis (MS) B-lymphocytes play a significant role in the pathological process development. In this regard, it is relevant to search for new biomarkers of B-lymphocytic origin, which can reflect the clinical features of this disease.

Aim of study – to assess the relationships between the level of blood serum 48 kDa form of unconventional myosin 1c (48 kDa Myo1c) in patients with multiple sclerosis and stage of this disease, its severity and type.

Materials and methods. 1 ml of blood serum was diluted 2-fold with phosphate buffer saline and then trichloroacetic acid (TCA) was added to 10 % of final concentration. The supernatant containing TCA-soluble compounds was isolated and mixed with acetone. Then, centrifugation and electrophoresis in the presence of sodium dodecylsulphate were performed. The 48 kDa Myo1c was identified by its molecular weight comparing after Coomassie Brillant Blue G staining of gel and Western blot analysis using polyclonal anti-Myo1c rabbit antibodies.

Results. The level of the 48 kDa Myo1c was significantly higher in the MS patients compared with that in healthy controls. The disease duration was shorter in patients with high level of the 48 kDa Myo1c, compared to patients with low level of the 48 kDa Myo1c. High level of the 48 kDa Myo1c was associated with a relapsing-remitting MS, while low level – with secondary progressive type of the disease. In the group with the low 48 kDa Myo1c level a disability rate was significantly higher, unlike in patients with the medium level of 48 kDa Myo1c.

Conclusions. An increased blood serum level of the 48 kDa Myo 1c in MS patients is combined with the early stage of the MS when its diagnostics is the most complicated.

 

References

D'Ambrosio, A., Pontecorvo, S., Colasanti, T., Zamboni, S., Francia, A., & Margutti, P. (2015). Peripheral blood biomarkers in multiple sclerosis. Autoimmunity Reviews, 14(12), 1097–110. doi: 10.1016/j.autrev.2015.07.014.

Fraussen, J., Claes, N., de Bock, L., & Somers, V. (2014). Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev, 13, 1126–37. doi: 10.1016/j.autrev.2014.07.002.

Wekerle, H. (2017). B cells in multiple sclerosis. Autoimmunity, 50(1), 57–60. doi: 10.1080/08916934.2017.1281914.

Myronovkij, S., Negrych, N., Nehrych, T., Redowicz, M., Souchelnytskyi, S., Stoika, R., & Kit, Y. (2016). Identification of a 48 kDa form of unconventional myosin 1c in blood serum of patients with autoimmune diseases. Biochemistry and Biophysics Reports, 5, 175–179. doi: 10.1016/j.bbrep.2015.12.001.

Maravillas-Montero, J., Gillespie, P., Patino-Lo´pez, G., Shaw, S., & Santos-Argumedo, L. (2011). Myosin 1c participates in B cell cytoskeleton rearrangements, is recruited to the immunologic synapse, and contributes to antigen presentation. J Immunol, 187(6), 3053–3063. doi: 10.4049/jimmunol.1004018.

Bond, L. M., Brandstaetter, H., Kendrick-Jones, J., & Buss, F. (2013). Functional roles for myosin 1c in cellular signaling pathways. Cell Signal, 25(1), 229–235. doi: 10.1016/j.cellsig.2012.09.026.

Menezes, S. M., Leal, F. E., Dierckx, T., Khouri, R., Decanine, D., Silva-Santos, G., Schnitman, S. V., et al. (2017). A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation. Frontiers in Immunology, 8, 97. doi: 10.3389/fimmu.2017.00097.

Chapouly, C., Tadesse Argaw, A., Horng, S., Castro, K., Zhang, J., Asp, L., Loo H., et al. (2015). Astrocytic TYMP and VEGFA drive blood–brain barrier opening in inflammatory central nervous system lesions. Brain, 138(6), 1548–1567. doi: 10.1093/brain/awv077.

Macchi, B., Marino-Merlo, F., Nocentini, U., Pisani, V., Cuzzocrea, S., Grelli, S., & Mastino, A. (2015). Role of inflammation and apoptosis in multiple sclerosis: comparative analysis between the periphery and the central nervous system. Journal of neuroimmunology, 287, 80–87. doi: 10.1016/j.jneuroim.2015.08.016.

Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H. P., Hemmer, B., et al. (2017). Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine, 376(3), 221–234. doi: 10.1056/NEJMoa1601277.

Downloads

How to Cite

1.
Nehrych NO, Nehrych TI, Myronovskyi SL, Shorobura MS, Nehrych OI, Kit YY, Stoika RS. Blood serum 48 kDa form of unconventional myosin 1c characterizes the early stage of multiple sclerosis. Zaporozhye Medical Journal [Internet]. 2018Jul.13 [cited 2024Dec.23];(4). Available from: http://zmj.zsmu.edu.ua/article/view/135589

Issue

No. 4 (2018)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)